文献速递肿瘤 PET/CT核素与放射性配体治疗

使用PSMA报告基因对CAR T细胞进行无创纵向PET/CT成像

Noninvasive longitudinal PET/CT imaging of CAR T cells using PSMA reporter gene.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-11-16

本研究通过慢病毒载体将截短的前列腺特异性膜抗原(ΔPSMA)报告基因导入靶向转铁蛋白受体的CAR T细胞(CAR-ΔPSMA),在体外和乳腺癌皮下异种移植模型中用[68Ga]Ga-PSMA-617 PET/CT定量监测CAR T细胞。结果显示CAR-ΔPSMA T细胞保留活化和杀伤能力,体外检测灵敏度为250 cells/mm3、体内为100 cells/mm3,随时间增加的[68Ga]Ga-PSMA-617信号可有效检测肿瘤部位CAR T细胞。

要点

  • CAR-ΔPSMA T细胞经ΔPSMA报告基因转导后保留活化和肿瘤杀伤能力。
  • [68Ga]Ga-PSMA-617 PET/CT检测CAR-ΔPSMA T细胞的灵敏度体外为250 cells/mm3、体内为100 cells/mm3。
  • 连续成像显示[68Ga]Ga-PSMA-617 PET/CT可特异性可视化肿瘤部位ΔPSMA+ CAR T细胞。

核心结论

  • 研究初步证实[68Ga]Ga-PSMA-617 PET/CT可在体外和体内可靠检测实体瘤中的CAR-ΔPSMA T细胞,为未来监测CAR T细胞治疗奠定基础。

研究设计与样本

  • 研究通过慢病毒载体编码TfR41BBζ-T2A-ΔPSMA转导T细胞构建CAR-ΔPSMA T细胞,在体外验证靶点表达、活化和细胞毒性,并在体外和体内分别确定[68Ga]Ga-PSMA-617 PET/CT检测CAR-ΔPSMA T细胞的最低阈值。
  • 在乳腺癌皮下异种移植模型中评估全身给药后监测CAR-ΔPSMA T细胞生物分布和浸润的可行性。

主要发现

  • CAR-ΔPSMA T细胞保留活化和肿瘤杀伤能力。
  • [68Ga]Ga-PSMA-617 PET/CT检测灵敏度体外为250 cells/mm3、体内为100 cells/mm3。
  • 连续成像显示[68Ga]Ga-PSMA-617 PET/CT可特异性可视化肿瘤部位ΔPSMA+ CAR T细胞,随时间增加的[68Ga]Ga-PSMA-617信号强度可有效检测体内CAR T细胞。

局限性

  • 原文结论称研究初步证实[68Ga]Ga-PSMA-617 PET/CT可可靠检测CAR-ΔPSMA T细胞,为未来监测CAR T细胞治疗奠定基础。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Chimeric antigen receptor (CAR) T cell therapy has achieved great success in treating hematologic malignancies. However, it is yet to prove effective in the treatment of solid tumors. Thus, it is necessary to develop appropriate methodology for the long-term, accurate, and quantitative evaluation of the distribution and activities of CAR T cells in solid tumors. In the present study, we engineered TfR ΔPSMA CAR (CAR-ΔPSMA) T cells, which targeted the transferrin receptor (TfR) expressed by tumor cells and could be tracked in vivo via a reporter gene encoding the truncated prostate specific membrane antigen (ΔPSMA). We then quantitatively monitored these CAR T cells in vitro and in vivo using [68Ga]Ga-PSMA-617 positron emission tomography (PET)/computed tomography (CT). METHODS: The CAR-ΔPSMA T cells were genetically engineered by transducing T cells with a lentiviral vector encoding TfR41BBζ-T2A-ΔPSMA. Firstly, the target expression, activation, and cytotoxicity of CAR-ΔPSMA T cells were validated in vitro. Secondly, the minimum thresholds of CAR-ΔPSMA T cells detection for [68Ga]Ga-PSMA-617 PET/CT were also determined in vitro and in vivo respectively. Lastly, the feasibility of monitoring the biodistribution and infiltration of CAR-ΔPSMA T cells after systematic administration was evaluated in the breast cancer subcutaneous xenograft model. RESULTS: The CAR-ΔPSMA T cells retained activation and tumor killing capacity after transduction of the ΔPSMA-encoding reporter gene. Next, the CAR-ΔPSMA T cells could be reliably tracked by [68Ga]Ga-PSMA-617 PET/CT, the detection sensitivity of which was 250 cells/mm3 in vitro and 100 cells/mm3 in vivo. Next, the sequential imaging assays revealed that [68Ga]Ga-PSMA-617 PET/CT could be used to specifically visualize ΔPSMA+ CAR T cells at the tumor site. The increase in the [68Ga]Ga-PSMA-617 signal intensity over time allowed us to effectively detect CAR T cells in vivo. CONCLUSION: Our findings preliminarily confirmed that [68Ga]Ga-PSMA-617 PET/CT could reliably detect CAR-ΔPSMA T cells in vitro and in vivo in solid tumors, laying the foundation for the monitoring CAR T cell therapy in the future.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Song X, Zhang Y, Lv X, et al. Noninvasive longitudinal PET/CT imaging of CAR T cells using PSMA reporter gene. Eur J Nucl Med Mol Imaging. 2023. PMID: 37971500. doi:10.1007/s00259-023-06508-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。